Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)

This is a multi-center, evaluator-blinded, randomized, open-label, proof of concept trial to explore possible beneficial effect of adjunctive oral minocycline on acute ischemic stroke (AIS) undergoing endovascular treatment due to basilar artery occlusion (BAO). Minocycline has excellent safety profiles, have been previously demonstrated individually to reduce infarction in animal models of stroke, and have potentially mechanisms of antioxidant, anti-inflammatory, anti-apoptotic and protection of blood-brain barrier. However, it is not known whether minocycline can reduce futile recanalization of endovascular treatment, and improve the outcome of patients with AIS due to BAO. Eligible and willing subjects will be randomly assigned to the treatment group or the control group. The treatment group will receive 200 mg oral minocycline, followed by 100 mg every 12 hours times for a total of 5 days. Both groups will receive endovascular thrombectomy and standard medical. The treatment with minocycline will start as soon as possible after randomization. Considering the risk of difficulty in feeding tube before EVT, minocycline administered within one hours after EVT is acceptable. Measures of stroke severity and disability will be recorded at baseline and through the follow-up periods (90 days). The evaluator will be blind to the allocation of patients further minimizing the bias.

NCT Number	NCT05512910
Lead Sponsor	Xijing Hospital Collaborators: Xi'an No.3 Hospital, Xi'an Gaoxin Hospital, First People's Hospital of Xianyang, Xi'an XD Group Hospital, Central Hospital of Gansu Province
Conditions	Ischemic Stroke, Acute, Minocycline, Endovascular Treatment, Basilar Artery Occlusion
Enrollment	90 participants
Start Date	2023-03-04
Primary Completion	2025-03-11 (estimated)
Study Completion	2025-06-04 (estimated)
Updated on ClinicalTrials.gov	2025-05-30